Treatment of Severe Inflammatory Tinea Capitis (Kerion)
For severe inflammatory tinea capitis (kerion), initiate oral antifungal therapy immediately without waiting for culture results, choosing either griseofulvin or terbinafine based on the most likely causative organism from local epidemiology. 1
Immediate Management Approach
When you encounter a kerion (characterized by a boggy, pustular, tender scalp mass with alopecia), start treatment immediately. The presence of kerion, along with cardinal signs of scale, lymphadenopathy, or alopecia, justifies empiric therapy while awaiting mycological confirmation. 1 Delaying treatment risks permanent scarring alopecia—a critical morbidity outcome.
First-Line Oral Antifungal Selection
Your choice depends on the suspected dermatophyte:
For Trichophyton species (T. tonsurans, T. violaceum, T. soudanense):
Terbinafine is superior 1
- < 20 kg: 62.5 mg daily for 2-4 weeks
- 20-40 kg: 125 mg daily for 2-4 weeks
- > 40 kg: 250 mg daily for 2-4 weeks
For Microsporum species (M. canis, M. audouinii):
Griseofulvin is more effective 1
- < 50 kg: 15-20 mg/kg/day (single or divided dose) for 6-8 weeks
- > 50 kg: 1 g daily for 6-8 weeks
- Take with fatty food to enhance absorption 1
Critical caveat: Terbinafine fails against Microsporum because it cannot reach adequate concentrations in prepubertal children's hair shafts and doesn't get excreted in sweat/sebum to reach scalp surface arthroconidia. 1 Conversely, griseofulvin requires longer treatment for Trichophyton (potentially 12-18 weeks). 1
Essential Adjunctive Measures
Topical therapy alone is inadequate 1—oral therapy is mandatory for clinical and mycological cure. However, add antifungal shampoos (ketoconazole 2%, selenium sulfide 1%, or povidone-iodine) to reduce spore transmission. 1
The Corticosteroid Controversy
Despite historical recommendations, oral or intralesional corticosteroids are unnecessary adjuncts for kerion treatment in urban settings where Trichophyton tonsurans predominates. 2 The evidence shows that directing therapy toward the underlying dermatophyte without steroids achieves excellent outcomes while avoiding unnecessary immunosuppression.
Treatment Failure Algorithm
If no clinical improvement occurs after the initial treatment course:
First, assess: compliance, drug absorption, reinfection, or ingrown hairs (a recently recognized aggravating factor visible on dermatoscopy). 3
If clinical improvement but persistent positive mycology: Continue current therapy 2-4 weeks longer. 1
If no initial improvement, switch to second-line:
For refractory cases: Consider fluconazole or voriconazole in exceptional circumstances. 1
Critical Infection Control Measures
- Allow school/nursery attendance once appropriate therapy is started 1
- Screen and treat all family members for T. tonsurans cases—over 50% may harbor infection, often occult. 1 Failure to treat household contacts leads to high recurrence rates
- Disinfect fomites (hairbrushes, combs) with bleach or 2% sodium hypochlorite solution 1
Monitoring and Endpoint
The treatment endpoint is mycological cure, not just clinical improvement. 1 Continue repeat mycology sampling until clearance is documented. This prevents relapse and permanent scarring—the most devastating outcome affecting quality of life.
Important Pitfalls to Avoid
- Don't use terbinafine empirically without knowing local epidemiology—if Microsporum predominates in your area, you'll face treatment failure
- Don't delay treatment waiting for culture in obvious kerion cases—permanent scarring alopecia is preventable with prompt therapy 4
- Don't stop at clinical improvement—mycological persistence leads to relapse
- Don't forget family screening for anthropophilic species, particularly T. tonsurans
The British Association of Dermatologists guidelines 1 provide the most comprehensive, evidence-based framework for kerion management, emphasizing species-directed therapy as the cornerstone of successful treatment and prevention of permanent alopecia.